drugset
drugset / Trial / NCT03547037

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers

NCT03547037 ↗

Phase 1 Completed 22 enrolled Janssen Pharmaceutical K.K.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The primary purpose of this study is to identify the recommended Phase 2 dose (RP2D) of JNJ-63723283 as a monotherapy (Phase 1a part) and to identify the RP2D of JNJ-63723283 when administered in combination with Erdafitinib (Phase 1b part).

Timeline

Start
2018-08-31
Primary completion
2022-07-04
Completion
2022-07-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetrelimab Monoclonal antibody — Intravenous
Subject Erdafitinib Small molecule — Oral

Indications

neoplasm